Liquidia Corporation's lead drug Yutrepia generated approximately $130 million in first-quarter 2026 sales, helping the company post its third consecutive profitable quarter. The inhaled dry-powder formulation of treprostinil, approved by the FDA in May 2025 for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, has seen more than 4,500 unique prescriptions, around 3,750 patients initiating treatment, and nearly 1,000 prescribing physicians since its June 2025 launch. Liquidia faces intense competition from United Therapeutics' extensive PAH portfolio, which includes injectable, oral, and inhaled treprostinil products, as well as from Johnson & Johnson's Uptravi and Opsumit. The company is planning studies to evaluate Yutrepia for additional indications, including pulmonary hypertension associated with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Liquidia shares have surged 126% year to date, and the Zacks Consensus Estimate for 2026 earnings per share has risen to $3.02 from $1.50 over the past 60 days.
Liquidia Technologies IncYutrepia generated $130M in Q1 sales with strong prescription and patient initiation numbers.
United Therapeutics CorporationLiquidia's Yutrepia competes with United Therapeutics' treprostinil products, potentially eroding market share.
Johnson & Johnson